Amisulpride	amisulpride	O	O	OTHERS	I
related	related	O	O	O	O
tic-like	tic-like	O	O	O	O
symptoms	symptoms	O	O	O	O
in	in	O	O	O	O
an	an	O	O	O	O
adolescent	adolescent	O	O	O	O
schizophrenic	schizophrenic	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Tic	tic	O	DISEASE	OTHERS	I
disorders	disorders	O	DISEASE	OTHERS	I
can	can	O	O	O	O
be	be	O	O	O	O
effectively	effectively	O	O	O	O
treated	treated	O	O	O	O
by	by	O	O	O	O
atypical	atypical	O	O	O	O
antipsychotics	antipsychotics	CHEMICALS	O	OTHERS	I
such	such	O	O	O	O
as	as	O	O	O	O
risperidone	risperidone	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
olanzapine	olanzapine	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
ziprasidone	ziprasidone	O	O	OTHERS	I
.	.	O	O	O	O

However	however	O	O	O	O
,	,	O	O	O	O
there	there	O	O	O	O
are	are	O	O	O	O
two	two	O	O	O	O
case	case	O	O	O	O
reports	reports	O	O	O	O
that	that	O	O	O	O
show	show	O	O	O	O
tic-like	tic-like	O	O	O	O
symptoms	symptoms	O	O	O	O
,	,	O	O	O	O
including	including	O	O	O	O
motor	motor	O	O	O	O
and	and	O	O	O	O
phonic	phonic	O	O	O	O
variants	variants	O	O	O	O
,	,	O	O	O	O
occurring	occurring	O	O	O	O
during	during	O	O	O	O
treatment	treatment	O	O	O	O
with	with	O	O	O	O
quetiapine	quetiapine	O	O	OTHERS	I
or	or	O	O	O	O
clozapine	clozapine	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

We	we	O	O	O	O
present	present	O	O	O	O
a	a	O	O	O	O
15-year-old	15-year-old	O	O	O	O
girl	girl	O	O	O	O
schizophrenic	schizophrenic	O	DISEASE	OTHERS	I
who	who	O	O	O	O
developed	developed	O	O	O	O
frequent	frequent	O	O	O	O
involuntary	involuntary	O	O	O	O
eye-blinking	eye-blinking	O	O	O	O
movements	movements	O	O	O	O
after	after	O	O	O	O
5	5	O	O	O	O
months	months	O	O	O	O
of	of	O	O	O	O
amisulpride	amisulpride	O	O	OTHERS	I
treatment	treatment	O	O	O	O
(	(	O	O	O	O
1000	1000	O	O	O	O
mg	mg	O	O	OTHERS	I
per	per	O	O	O	O
day	day	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
tic-like	tic-like	O	O	O	O
symptoms	symptoms	O	O	O	O
resolved	resolved	O	O	O	O
completely	completely	O	O	O	O
after	after	O	O	O	O
we	we	O	O	O	O
reduced	reduced	O	O	O	O
the	the	O	O	O	O
dose	dose	O	O	O	O
of	of	O	O	O	O
amisulpride	amisulpride	O	O	OTHERS	I
down	down	O	O	O	O
to	to	O	O	O	O
800	800	O	O	O	O
mg	mg	O	O	OTHERS	I
per	per	O	O	O	O
day	day	O	O	O	O
.	.	O	O	O	O

However	however	O	O	O	O
,	,	O	O	O	O
her	her	O	O	O	O
psychosis	psychosis	O	DISEASE	OTHERS	I
recurred	recurred	O	O	O	O
after	after	O	O	O	O
the	the	O	O	O	O
dose	dose	O	O	O	O
reduction	reduction	O	O	O	O
.	.	O	O	O	O

We	we	O	O	O	O
then	then	O	O	O	O
placed	placed	O	O	O	O
her	her	O	O	O	O
on	on	O	O	O	O
an	an	O	O	O	O
additional	additional	O	O	O	O
100	100	O	O	O	O
mg	mg	O	O	OTHERS	I
per	per	O	O	O	O
day	day	O	O	O	O
of	of	O	O	O	O
quetiapine	quetiapine	O	O	OTHERS	I
.	.	O	O	O	O

She	she	O	O	O	O
has	has	O	O	O	O
been	been	O	O	O	O
in	in	O	O	O	O
complete	complete	O	O	O	O
remission	remission	O	O	O	O
under	under	O	O	O	O
the	the	O	O	O	O
combined	combined	O	O	O	O
medications	medications	O	O	O	O
for	for	O	O	O	O
more	more	O	O	O	O
than	than	O	O	O	O
one	one	O	O	O	O
year	year	O	O	O	O
and	and	O	O	O	O
maintains	maintains	O	O	O	O
a	a	O	O	O	O
fair	fair	O	O	O	O
role	role	O	O	O	O
function	function	O	O	O	O
.	.	O	O	O	O

No	no	O	O	O	O
more	more	O	O	O	O
tic-like	tic-like	O	O	O	O
symptoms	symptoms	O	O	O	O
or	or	O	O	O	O
other	other	O	O	O	O
side	side	O	O	O	O
effects	effects	O	O	O	O
have	have	O	O	O	O
been	been	O	O	O	O
reported	reported	O	O	O	O
.	.	O	O	O	O

Together	together	O	O	O	O
with	with	O	O	O	O
previously	previously	O	O	O	O
reported	reported	O	O	O	O
cases	cases	O	O	O	O
,	,	O	O	O	O
our	our	O	O	O	O
patient	patient	O	O	O	O
suggests	suggests	O	O	O	O
that	that	O	O	O	O
tic-like	tic-like	O	O	O	O
symptoms	symptoms	O	O	O	O
might	might	O	O	O	O
occur	occur	O	O	O	O
in	in	O	O	O	O
certain	certain	O	O	O	O
vulnerable	vulnerable	O	O	O	O
individuals	individuals	O	O	O	O
during	during	O	O	O	O
treatment	treatment	O	O	O	O
with	with	O	O	O	O
atypical	atypical	O	O	O	O
antipsychotics	antipsychotics	CHEMICALS	O	OTHERS	I
such	such	O	O	O	O
as	as	O	O	O	O
quetiapine	quetiapine	O	O	OTHERS	I
,	,	O	O	O	O
clozapine	clozapine	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
or	or	O	O	O	O
amisulpride	amisulpride	O	O	OTHERS	I
.	.	O	O	O	O

